Many CNS diseases of primarily noninflammatory origin, such as chronic neurodegenerative diseases, stroke and trauma, display inflammatory features. Conversely, damage to nerve cells and axons has emerged as a clinically important parameter of autoimmune neuroinflammatory conditions such as multiple sclerosis. Experimental data are conflicting as to whether neuroinflammatory reactions should be regarded as detrimental, or as an apt response serving to minimize nervous tissue damage. Despite this, modulation of inflammation is one of the most dynamic areas in the search for new therapeutic targets for a spectrum of CNS diseases. Recent developments in the field have unravelled an intricate regulation of neuroinflammation and disclosed several avenues that, with further exploration, may result in new ways of treating common and disabling CNS diseases.